Australian-based reproductive biotechnology company, Memphasys Limited (ASX: MEM), has been granted two new patents for the Felix System by the Australian Patent Office. These two new patents enhance MEM’s patent portfolio and ensure the value and integrity of the Felix device is properly protected in all markets.
The two patents cover the subjects Electrophoresis device, and Sperm separation by electrophoresis and are in place for 20 years.
Felix is an automated device with a single-use cartridge that gently separates high-quality sperm from a semen sample in six minutes using electrophoresis for use in human IVF procedures. Felix is MEM’s first commercial product.
The patents are essential to protecting MEM’s unique intellectual property globally,” MEM Chief Executive Officer, Alison Coutts, said.
